Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-09-04 am EDT
|
5-day change | 1st Jan Change | ||
| 72.72 EUR | -1.01% |
|
+0.50% | +16.54% |
| Aug. 24 | Wall Street's Three-Way Stress Test |  |
| Jul. 23 | Eurofins Scientific SE, H1 2026 Earnings Call, Jul 23, 2026 |
| Market Cap | 12.62B 14.67B 11.88B 10.85B 20.3B 1,385B 20.35B 140B 54.46B 711B 55.09B 53.89B 2,289B | P/E 2026 * |
24.2x | P/E 2027 * | 19.2x |
|---|---|---|---|---|---|
| Enterprise Value | 15.97B 18.56B 15.03B 13.73B 25.68B 1,753B 25.75B 178B 68.91B 899B 69.7B 68.18B 2,897B | EV / Sales 2026 * |
2.11x | EV / Sales 2027 * | 1.95x |
| Free-Float |
60.39% | Yield 2026 * |
1.11% | Yield 2027 * | 1.26% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
Tradegate
| ESF0 | Real-time | |
|
OTC Markets
| ERFSF | Delayed | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote | |
|
Xetra
| ESF0 | Delayed |
Last Transcript : Eurofins Scientific SE
| 1 day | -1.01% | ||
| 1 week | +0.50% | ||
| Current month | +0.25% | ||
| 1 month | +5.67% | ||
| 3 months | +11.81% | ||
| 6 months | +8.80% | ||
| Current year | +16.54% |
| 1 week | 71.1 |  | 74.78 |
| 1 month | 68.62 | | 74.78 |
| Current year | 56.84 | | 74.78 |
| 1 year | 54.86 | | 74.78 |
| 3 years | 39.47 | | 74.78 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.01% | +0.50% | +15.83% | +27.98% | 14.82B | |
| -2.54% | -2.84% | -1.90% | +14.52% | 50.35B | |
| -0.40% | +1.03% | +439.20% | +499.20% | 45.2B | |
| -1.42% | +2.30% | +45.46% | +19.36% | 44.71B | |
| -1.22% | -2.31% | +12.40% | +71.48% | 41.24B | |
| +0.53% | -1.67% | +15.16% | +49.88% | 33.08B | |
| -0.21% | +9.14% | - | - | 17.81B | |
| -0.35% | -1.56% | +22.59% | +116.19% | 16.56B | |
| -1.65% | -1.03% | +77.75% | +37.63% | 14B | |
| +0.78% | -3.04% | -6.53% | -37.25% | 12.62B | |
| Average | -0.75% | -0.35% | +68.89% | +88.78% | 29.04B | |
| Weighted average by Cap. | -0.96% | -0.60% | +89.57% | +114.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.59B 8.82B 7.14B 6.52B 12.2B 833B 12.23B 84.36B 32.74B 427B 33.11B 32.39B 1,376B | 8.01B 9.31B 7.54B 6.88B 12.88B 879B 12.91B 89.05B 34.55B 451B 34.95B 34.19B 1,453B |
| Net income | 531M 617M 500M 456M 854M 58.25B 856M 5.9B 2.29B 29.89B 2.32B 2.27B 96.28B | 660M 767M 621M 567M 1.06B 72.38B 1.06B 7.33B 2.85B 37.14B 2.88B 2.82B 120B |
| Net Debt | 3.35B 3.89B 3.15B 2.88B 5.38B 367B 5.4B 37.23B 14.45B 189B 14.61B 14.3B 607B | 3.01B 3.5B 2.84B 2.59B 4.85B 331B 4.86B 33.51B 13B 170B 13.15B 12.86B 547B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-04 | €72.72 | -1.01% | 167,941 |
| 26-09-03 | €73.46 | +0.93% | 307,393 |
| 26-09-02 | €72.78 | +1.70% | 228,096 |
| 26-09-01 | €71.56 | -1.35% | 247,022 |
| 26-08-31 | €72.54 | +0.25% | 520,172 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
